Patents Assigned to Gelgene Corporation
  • Deacetylase inhibitor therapy
    Patent number: 9259452
    Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: February 16, 2016
    Assignees: Gelgene Corporation, The United States of America Department of Health and Human Services
    Inventors: William McCulloch, Richard L. Piekarz, Susan E. Bates